TY - JOUR
T1 - Transplantation of CD34+ hematopoietic progenitor cells
AU - Berenson, Ronald J.
AU - Shpall, Elizabeth J.
AU - Auditore-Hargreaves, Karen
AU - Heimfeld, Shelly
AU - Jacobs, Cindy
AU - Krieger, Monica S.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1996
Y1 - 1996
N2 - We have developed an avidin-biotin immunoadsorption technique in conjunction with a monoclonal anti-CD34 antibody that is capable of selecting CD34+ progenitor cells from marrow and mobilized peripheral blood. Clinical studies with these CD34+ selected cells have shown that the cells are capable of rapid and durable engraftment. In addition, there is significant less infusional toxicity to the patient because the volume in which the CD34+ selected cells are contained is much less than that of a typical marrow or apheresis buffy coat. Selection of CD34+ progenitor cells also offers other potential advantages, including T-cell depletion of allografts and tumor cell depletion of autografts. CD34+ selection can also be used to facilitate other manipulations of marrow and peripheral blood, including gene transfection, ex vivo stem cell expansion, tumor purging, and progenitor cell banking. Future graft engineering studies are expected to clarify these relationships and enable refinement of the graft to the point at which GVHD can be minimized, graft survival maximized, and relapse-free survival prolonged.
AB - We have developed an avidin-biotin immunoadsorption technique in conjunction with a monoclonal anti-CD34 antibody that is capable of selecting CD34+ progenitor cells from marrow and mobilized peripheral blood. Clinical studies with these CD34+ selected cells have shown that the cells are capable of rapid and durable engraftment. In addition, there is significant less infusional toxicity to the patient because the volume in which the CD34+ selected cells are contained is much less than that of a typical marrow or apheresis buffy coat. Selection of CD34+ progenitor cells also offers other potential advantages, including T-cell depletion of allografts and tumor cell depletion of autografts. CD34+ selection can also be used to facilitate other manipulations of marrow and peripheral blood, including gene transfection, ex vivo stem cell expansion, tumor purging, and progenitor cell banking. Future graft engineering studies are expected to clarify these relationships and enable refinement of the graft to the point at which GVHD can be minimized, graft survival maximized, and relapse-free survival prolonged.
UR - http://www.scopus.com/inward/record.url?scp=0030445227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030445227&partnerID=8YFLogxK
U2 - 10.3109/07357909609076903
DO - 10.3109/07357909609076903
M3 - Review article
C2 - 8951362
AN - SCOPUS:0030445227
SN - 0735-7907
VL - 14
SP - 589
EP - 596
JO - Cancer Investigation
JF - Cancer Investigation
IS - 6
ER -